Brian is a cardiologist and genetic epidemiologist who was educated and trained at Yale, Harvard, Oxford and Cambridge Universities. He is currently Professor / Director of Research in Translational Therapeutics, and Executive Director of the Centre for Naturally Randomized Trials at the University of Cambridge, UK; and Professor of Cardiovascular Medicine at the University of Milan, Italy. His previous posts included Chief of Cardiology at Wayne State University School of Medicine in the US; Chief Medical and Scientific Officer for a public-private collaboration in Beijing; and CEO of a biotechnology company. His research focuses on using Mendelian randomization to design ‘naturally randomized trials’ to generate randomized evidence that can be used to improve the drug discovery and development process; inform the optimal design of randomized trials; fill evidence gaps when a randomized trial is not possible or practical; and define the practice of precision cardiovascular medicine.

Contributions

Panel Discussion: Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?91th EAS Congress 2023TG vs apo B reductionElevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?91th EAS Congress 2023Estimating the magnitude of LDL-C reduction needed to overcome the increased risk of atherosclerotic cardiovascular events caused by LP(A) to guide clinical managementLate breaker session 290th EAS Congress 2022WHF Session 1: WHF Roadmap on Cholesterol update - Discussion and Q&A90th EAS Congress 2022WHF Session 1: WHF Roadmap on Cholesterol updateCumulative exposure, estimating benefits of early invention of lifetime risk90th EAS Congress 2022WHF Session 1: WHF Roadmap on Cholesterol updateDebate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention - Discussion and Q&A90th EAS Congress 2022ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemiaWhat is new in prevention in apparently healthy persons?90th EAS Congress 2022ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemiaReimagining population health-the time is now - Discussion and Q&AReimagining population health-the time is now90th EAS Congress 2022Reimagining prevention - Using AI and causal estimates to preserve health?Reimagining population health-the time is now90th EAS Congress 2022Predictors of residual risk from Lp(a) to apo B89th EAS Congress 2021(ReviewLipidologyLipid risk factors)Mendelian randomizationIntro to Clinical LipidologyGenetics for the identification of therapeutic targets in dyslipidaemiaEAS AC in LipidologyGuidelines - Diabetic patientsAn Introduction to Clinical LipidologyThe genetic evidence for inhibiting the cholesterol synthesis pathway to control LDL cholesterol87th EAS Congress 2019Lessons from genetics - risk-score and novel candidates86th EAS Congress 2018Apo B containing lipoproteins a better target for CV risk reduction?86th EAS Congress 2018Using naturally randomized genetic evidence to understand heritability of coronary artery disease?85th EAS Congress 2017Life time exposure to LDL-cholesterol is it the key to CVD risk?85th EAS Congress 2017